- Conditions
- Defecation Frequency
- Interventions
- Control (placebo), Yeast mannan
- Dietary Supplement
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2593–2616
of 4,251
matching trials from the local directory fallback.
- Conditions
- Glioblastoma
- Interventions
- Optune® device, Pembrolizumab, Placebo, Temozolomide
- Device · Drug
- Lead sponsor
- NovoCure GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 741 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 31 more
- Conditions
- Netherton Syndrome
- Interventions
- BCX17725, Placebo
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Palo Alto, California • San Diego, California • New Haven, Connecticut + 2 more
- Conditions
- Chronic Hepatitis B Virus Infection, Hepatitis B
- Interventions
- Bepirovirsen, Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 5
- States / cities
- San Francisco, California • San Jose, California • Minneapolis, Minnesota + 2 more
- Conditions
- Hepatitis B
- Interventions
- Bepirovirsen, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Bakersfield, California • San Francisco, California • Orlando, Florida + 4 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- MTT with antibiotic preconditioning + fiber supplementation, MTT with antibiotic preconditioning + placebo supplementation, MTT with placebo + placebo supplementation.
- Drug · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- GSK3862995B, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 10
- States / cities
- Yuma, Arizona • Hialeah, Florida • Orange City, Florida + 7 more
- Conditions
- End Stage Renal Disease
- Interventions
- Empagliflozin 10 MG, Placebo
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Fuchs
- Interventions
- Topical Placebo, Topical Ripasudil
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Palo Alto, California • Sacramento, California • Palm Beach Gardens, Florida + 3 more
- Conditions
- Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy
- Interventions
- Placebo, Ripasudil
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 8
- States / cities
- Palo Alto, California • Sacramento, California • Palm Beach Gardens, Florida + 3 more
- Conditions
- Body Weight, Nutrition Disorders, Nutritional and Metabolic Diseases, Obesity, Overnutrition, Overweight, Overweight and/or Obesity, Overweight or Obesity
- Interventions
- PF-08653944, PF-08653945, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 940 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 53
- States / cities
- Sun City West, Arizona • Canoga Park, California • Fountain Valley, California + 45 more
- Conditions
- Obesity
- Interventions
- ABBV-295, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Anaheim, California • Grayslake, Illinois
- Conditions
- Infertility (IVF Patients)
- Interventions
- Placebo, hMG subcutaneous injection
- Drug
- Lead sponsor
- Granata Bio Corporation
- Industry
- Eligibility
- 18 Years to 42 Years · Female only
- Enrollment
- 659 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 16
- States / cities
- Encino, California • Norwalk, Connecticut • Newark, Delaware + 13 more
- Conditions
- Alzheimer's Disease
- Interventions
- Placebo, VHB937
- Other · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more
- Conditions
- Multiple System Atrophy
- Interventions
- Placebo, TEV-56286
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 349 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 19
- States / cities
- La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more
- Conditions
- Infectious Disease, Respiratory Syncytial Virus (RSV)
- Interventions
- JCXH-108, Placebo
- Biological · Other
- Lead sponsor
- Immorna Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 3
- States / cities
- Jupiter, Florida • New Orleans, Louisiana • St Louis, Missouri
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Andecaliximab, Placebo
- Drug
- Lead sponsor
- Ashibio Inc
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- HIV-1-infection
- Interventions
- B/F/TAF, Bictegravir/Lenacapavir (BIC/LEN) FDC, Lenacapavir, Placebo to match B/F/TAF, Placebo to match BIC/LEN FDC, Placebo to match Lenacapavir
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 577 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more
- Conditions
- Hypersensitivity Pneumonitis, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder), Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Interstitial Lung Disease With Systemic Sclerosis, Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
- Interventions
- AP01, Placebo
- Drug · Other
- Lead sponsor
- Avalyn Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 46 more
- Conditions
- Misuse, Opioid
- Interventions
- Olanzapine, Placebo
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Arterial Stiffness, Cognitive Decline, White Matter Lesions
- Interventions
- Placebo, S-equol
- Drug
- Lead sponsor
- Akira Sekikawa
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 369 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Winston-Salem, North Carolina • Pittsburgh, Pennsylvania
- Conditions
- Primary Prevention of Atherosclerotic Cardiovascular Disease
- Interventions
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 79 Years
- Enrollment
- 14,012 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 241
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 187 more
- Conditions
- Hepatitis B
- Interventions
- Bepirovirsen, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 5
- States / cities
- Sacramento, California • San Jose, California • Colorado Springs, Colorado + 2 more
- Conditions
- Prostate Cancer
- Interventions
- Placebo plus enzalutamide, talazoparib plus enzalutamide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 599 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 26 more